The Italian pharmaceutical company Angelini announced the commercialisation of its AOS Wound Care Solution in the United States, after clearance for sale by the FDA. The operation is the result of an exclusive partnership with the Swiss Company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology Tehclo®, for the production of acidic super-oxidizing solutions. The product helps cleanse and moisten the wound environment by removing dirt, debris and foreign material by flushing across the wound and is intended for use, under the supervision of healthcare professionals, to treat acute and chronic dermal lesions (such as leg ulcers, post-surgical wounds or 1st and 2nd degree burns) and minor cuts, burns, skin irritations and superficial abrasions.
The Wound Care Solution has an acidic pH between 2.5 and 3.0 and an excellent cell viability preservation features that do not interfere with the natural physiological healing process and epthelialization. Its antimicrobial preservative effectiveness has been demonstrated by in vitro testing against P. aeruginosa, E. coli, S. aureus, S. epidermidis, S. pyogenes, E. gergoviae, C. albicans and A. niger.